Cardiovascular disease is the leading cause of death in the set of chronic kidney disease (CKD) patients, whether on renal replacement therapy or conservative treatment. A better understanding of cardiovascular risk factors, diagnostic approach and management are central keys to develop strategies to reduce cardiovascular mortality among those patients. This review article discusses some aspects of pathophysiology, investigation methods and current treatment of cardiovascular disease in CKD patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oral GVHD post-cardiac xenograft valve replacement: a case report.
J Cardiothorac Surg
December 2024
Department of Anatomical Pathology, Pathology, King Faisal Specialist Hospital and Research Centre, Al-Rawdah Street, Jeddah, Saudi Arabia.
Background: Graft versus host disease (GVHD) is an autoimmune disease that affects the oral cavity as well as other parts of the body. Oral GVHD occurs in 45-83% of cases, and chronic GVHD observed in 30-50% of cases usually manifests as an oral presentation.
Case Presentation: In this case report, a 13 years-old girl was referred to the periodontics clinic from the pediatric dentistry clinics for proper diagnosis and management of the oral presentations observed after receiving a prosthetic valve replacement 2 years ago.
The modified role including mediating and synergistic interactive effects of glucose tolerance status in the associations between relative fat mass and the risks of cardiovascular disease and all-cause mortality from the 4C cohort study.
Diabetol Metab Syndr
December 2024
Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.
Background: To investigate the associations between relative fat mass (RFM) and clinical outcomes in different glucose tolerance statuses and the modified effect of glucose tolerance status.
Methods: We analyzed 8,224 participants from a Chinese cohort study, who were classified into normal glucose status (NGT), prediabetes, and diabetes. Outcomes included fatal, nonfatal cardiovascular disease (CVD) events and all-cause mortality.
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer.
Biomark Res
December 2024
Department of Microbiology and Immunology, Chonnam National University Medical School, Hwasunup, Jeollanamdo, 58128, Republic of Korea.
The immune system continuously interacts with tumors, possibly leading to systemic alterations in circulating immune cells. However, the potential of these cancer-associated changes for diagnostic purposes remains poorly explored. To investigate this, we conducted a comprehensive flow cytometric analysis of 452 peripheral blood mononuclear cell (PBMC) samples from 206 non-small-cell lung cancer (NSCLC) patients, 100 small-cell lung cancer (SCLC) patients, 94 healthy individuals, and 52 benign lung disease (BLD) patients.
View Article and Find Full Text PDFAzvudine efficacy in reducing mortality in COVID-19 patients.
Eur J Med Res
December 2024
Department of Emergency, First Affiliated Hospital of Gannan Medical University, 128 Jinling Road, Zhanggong District, Ganzhou City, Jiangxi Province, China.
Background: Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, efficacy, and target populations of these novel therapeutic drugs are necessary. This study included mild, moderate, severe, and critical COVID-19 patients to evaluate azvudine's effectiveness across different severity levels.
View Article and Find Full Text PDFImpact of frailty on outcomes following coronary artery bypass grafting: a systematic review and meta-analysis.
BMC Surg
December 2024
Department of Geriatric Medicine, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, 9 Jiaowei Road, Wenzhou city, Zhejiang Province, 325000, China.
Background: Coronary artery bypass grafting (CABG) remains the preferred treatment for complex multi-vessel coronary artery disease, offering substantial long-term benefits. Non-cardiac comorbidities such as frailty may significantly affect the outcomes of this procedure. However, the exact impact of frailty on CABG outcomes remains unclear, particularly given its exclusion from many pivotal revascularization trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!